Intellia Therapeutics (NASDAQ:NTLA) Given “Neutral” Rating at Wedbush

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reaffirmed by investment analysts at Wedbush in a research note issued on Thursday,RTT News reports. They currently have a $14.00 price objective on the stock. Wedbush’s price objective suggests a potential downside of 16.32% from the stock’s previous close.

Several other analysts have also issued reports on NTLA. Robert W. Baird dropped their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Chardan Capital decreased their target price on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.94.

Intellia Therapeutics Stock Up 4.6 %

NASDAQ:NTLA opened at $16.73 on Thursday. Intellia Therapeutics has a 12-month low of $13.95 and a 12-month high of $34.87. The firm has a market capitalization of $1.70 billion, a P/E ratio of -3.05 and a beta of 1.81. The stock’s fifty day simple moving average is $19.17 and its 200-day simple moving average is $22.22.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.38) earnings per share. As a group, equities research analysts expect that Intellia Therapeutics will post -5.21 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NTLA. Dimensional Fund Advisors LP boosted its position in shares of Intellia Therapeutics by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock worth $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Thrivent Financial for Lutherans purchased a new position in Intellia Therapeutics in the 2nd quarter worth about $679,000. American Century Companies Inc. boosted its position in Intellia Therapeutics by 23.8% in the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock valued at $7,397,000 after buying an additional 63,550 shares during the period. Comerica Bank increased its position in shares of Intellia Therapeutics by 853.6% during the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after acquiring an additional 33,214 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after purchasing an additional 746,263 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.